MedApps is providing a revolutionary change to the way Coumadin or warfarin patients analyze their blood coagulation levels. Historically, patients on blood thinning medication have needed to travel to hospitals or Coumadin clinics for PT testing.
With over 2 million new people taking anticoagulation medication every year to prevent blood clots, stroke, and heart attacks – the need for careful monitoring of these users has never been greater, and correct medication dosing is important to assure the best outcomes for these patients.
MedApps allows these individuals the ability to test PT levels from the comfort of their home and avoid the need to travel for this analysis. Further, it has been demonstrated that patients who self-test, test in their “safe-zone” or therapeutic range 56% of the time – versus a 32% rate for patients receiving typical testing. A ten-year study of the ESCAT (Early Self-Controlled Anticoagulation Test) showed a 33% increased survival rate for self-testing patients over conventional therapy.
Current Reimbursement is currently available for PT/INR testing under CMS for coagulation monitoring, which includes reimbursement for professional review, training, equipment, supplies and connectivity.
MedApps is scheduled to deliver the first remote transmission system for PT/INR data in the industry in 2012 under IRB, pending FDA clearance.